1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 21,200 | 23,500 | 26.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | BASTIDE: Completion of the disposal of New Medical Concept, the holding company of EXPERF Group, to Sapio Group | 525 | Actusnews Wire | Caissargues, 1st June 2026 - Bastide Group announces the completion of the acquisition by Sapio Group of its subsidiary New Medical Concept, the holding company of the French EXPERF Group, a specialist... ► Artikel lesen | |
| 21.05. | BASTIDE: Groupe Bastide sells New Medical Concept, the holding company of EXPERF group - Erratum | 575 | Actusnews Wire | Caissargues, 21 May 2026 -Groupe Bastide today announced the signing of an agreement for the disposal of its subsidiary New Medical Concept, the holding company of the French group EXPERF, specialized... ► Artikel lesen | |
| 21.05. | BASTIDE: Groupe Bastide sells New Medical Concept, the holding company of EXPERF group | 534 | Actusnews Wire | Caissargues, 21 May 2026 -Groupe Bastide today announced the signing of an agreement for the disposal of its subsidiary New Medical Concept, the holding company of the French group EXPERF, specialized... ► Artikel lesen | |
| 13.05. | BASTIDE: Strong momentum for the first nine months of the financial year: up 7.2% on an organic basis | 792 | Actusnews Wire | Sustained growth in home healthcare services: up 8.5%
Solid growth of 5.2% in Homecare, including the one-off impact of the VPH* reform in the third quarter
2025-2026 targets confirmed
Caissargues... ► Artikel lesen | |
| 18.03. | BASTIDE: 2025-2026 half-year results | 1.075 | Actusnews Wire | Recurring operating margin: 9.0%, in line with the annual target
Operating profit up 12.5%
Operating free cash flow: €24.3 million, a threefold increase in one year
Significant improvement... ► Artikel lesen | |
| 12.02. | BASTIDE: Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent growth momentum in home healthcare services: 9.2% / Accelerated growth in the Homecare business, up 6.5% // 2025-2026 targets confirmed | 506 | Actusnews Wire | Caissargues, February 12, 2026 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-half 2025-2026, ending December 31, 2025.
In... ► Artikel lesen | |
| 13.11.25 | BASTIDE: Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in home healthcare services, up 10.7% / Homecare business up 4.7%, driven by the healthcare institutions business (up 8.5%) | 558 | Actusnews Wire | Caissargues, November 13, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025.
In... ► Artikel lesen | |
| 28.10.25 | BASTIDE: 2025-2026 financial calendar | 1.104 | Actusnews Wire | Caissargues, October 28, 2025
Events
Dates*
2025-2026 Q1 Revenue
Thursday November 13, 2025
2025-2026 H1 Revenue
Thursday February 12, 2026
2025-2026 H1 Results
Wednesday... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 22.10.25 | BASTIDE: 2024-2025 annual results in line with targets // 2025-26 outlook: Revenue of over EUR 510 million and recurring operating margin around 9%, Leverage of less than 3x and decrease in financial expenses | 1.022 | Actusnews Wire | Caissargues, October 22, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated... ► Artikel lesen | |
| 24.09.25 | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 885 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen | |
| 04.09.25 | BASTIDE: 2024-2025 revenue target met // 2024-2025 revenue from continuing operations: EUR 491 million, up 8% ( EUR 561 million, excluding impact of disposals) | 653 | Actusnews Wire | Caissargues, September 4, 2025
Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 46,345 | +1,09 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius verkauft 7,8 Millionen Fresenius Medical Care-Aktien im Wert von rund 300 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius verkauft 7,8 Millionen Fresenius Medical Care-Aktien im Wert von rund 300 Millionen... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,260 | -1,11 % | Siemens-Healthineers-Chef: 'Mir gefällt dieses Rumgenörgel nicht' | BERLIN (dpa-AFX) - Der Vorstandvorsitzende des Dax -Konzerns Siemens Healthineers, Bernhard Montag, hat die Anspruchshaltung vieler Wirtschaftslenker in Deutschland gegenüber der Politik kritisiert.... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 61,36 | +0,02 % | BrightSpring Health Services, Inc. Reports Second Quarter 2026 Financial Results and Increases Full Year 2026 Guidance | LOUISVILLE, Ky., July 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,360 | 0,00 % | Fresenius macht bei FMC Kasse - was jetzt zählt | ||
| ALIGNMENT HEALTHCARE | 13,920 | +0,14 % | Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics | Generates $1.3 billion in total revenue, representing 31.6% growth year-over-year Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 membersRaises the midpoint of all... ► Artikel lesen | |
| HEARTFLOW | 48,920 | -0,04 % | Biotech Stocks At 52-Week Highs - Vogenx, Pharvaris, Solventum, Inhibikase Therapeutics, HeartFlow | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 24, 2026, driven by positive results from clinical trials or an upcoming conference participation. Vogenx... ► Artikel lesen | |
| LIFESTANCE HEALTH GROUP | 12,150 | 0,00 % | LifeStance Health Group, Inc.: LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook | SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 31,280 | -2,00 % | 2,2 Milliarden Menschen mit Sehbeeinträchtigungen: Warum Augengesundheit für Carl Zeiss Meditec, Alcon & Co. zum Technologiemarkt wird - und wo Rise Nano Optics ins Spiel kommt | ||
| AVEANNA HEALTHCARE | 13,605 | -0,11 % | Aveanna Healthcare (AVAH) Just Ended A Four-Year Rate Fight | ||
| PROGYNY | 26,375 | 0,00 % | Progyny vor dem Boom?: Wells Fargo sieht bei dieser "Kinderwunsch-Aktie" 42 % Kurspotenzial | © Foto: SOPA Images - Sipa USAWells Fargo traut Progyny 42 Prozent Kurspotenzial zu. Das Geschäft mit Kinderwunsch-Leistungen könnte jetzt zum großen Wachstumstreiber werden Enthaltene Werte: US74340E1038Den... ► Artikel lesen | |
| BILLIONTOONE | 96,27 | 0,00 % | BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar | Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne... ► Artikel lesen | |
| GENEDX | 90,30 | +0,02 % | GeneDx study shows rapid genome sequencing benefits beyond ICUs | ||
| GERRESHEIMER | 25,400 | -0,70 % | EQS-Adhoc: Gerresheimer AG: Uwe Röhrhoff beendet Mandat als Interim-CEO | EQS-Ad-hoc: Gerresheimer AG / Schlagwort(e): Personalentscheidungen / Vorstand/Bedeutende Verträge
Gerresheimer AG: Uwe Röhrhoff beendet Mandat als Interim-CEO
24.08.2026 / 19:29... ► Artikel lesen | |
| DRAEGERWERK | 112,20 | +0,90 % | dpa-AFX-Überblick: UNTERNEHMEN vom 10.08.2026 - 15.15 Uhr | ROUNDUP: Hypoport bestätigt Jahresziele für 2026 - Aktie legt zu BERLIN - Der Finanzdienstleister Hypoport sieht sich auf Kurs zu seinen Jahreszielen. "Die geopolitischen Spannungen des ersten Halbjahres... ► Artikel lesen | |
| CLEARPOINT NEURO | 16,370 | 0,00 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Reports Second Quarter 2026 Results | Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT)... ► Artikel lesen |
Das Unternehmen BASTIDE LE CONFORT MEDICAL SA kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,13 % bei einem Aktienkurs von 21,950 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BASTIDE LE CONFORT MEDICAL SA finden Sie auf Wallstreet Online.